Search Results

You are looking at 1 - 10 of 625 items for :

  • All content x
Clear All
Free access

Günter Klöppel

Introduction Endocrine neoplasms can be divided according to the chemical nature of their secretion products into two groups. Neoplasms that produce and secrete (glyco)peptide hormones and biogenic amines comprise the first group. The second group

Free access

Guido Rindi and Frediano Inzani

types or, perhaps, neuroendocrine-committed cells do transform, generating neoplasms. Neoplasms made by cells with a neuroendocrine phenotype are today defined as neuroendocrine neoplasia (NEN). Similar to neuroendocrine cells, NEN are observed in pure

Free access

Yulong Li and William F Simonds

different treatment approaches. Being familiar with their unique features and natural history may facilitate diagnosis and help to establish individua­lized management to improve outcomes. We herein summarize and update the knowledge on endocrine neoplasms

Free access

Fritz-Line Vélayoudom-Céphise, Pierre Duvillard, Lydia Foucan, Julien Hadoux, Cecile N Chougnet, Sophie Leboulleux, David Malka, Joël Guigay, Diane Goere, Thierry Debaere, Caroline Caramella, Martin Schlumberger, David Planchard, Dominique Elias, Michel Ducreux, Jean-Yves Scoazec, and Eric Baudin

Introduction Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) are rare tumors defined by the expression of specific diagnostic biomarkers ( Baudin 2007 , Modlin et al . 2008 , Yao et al . 2008 ). Their prognosis is best characterized by

Free access

Krystallenia I Alexandraki, Gregory A Kaltsas, Simona Grozinsky-Glasberg, Eleftherios Chatzellis, and Ashley B Grossman

Introduction Neuroendocrine neoplasms (NENs), previously named ‘carcinoid’ tumours, most frequently occur in the gastrointestinal (GI) tract (54.5%) and have been an area of ongoing interest in the field of many different disciplines including

Free access

Luis V Syro, Fabio Rotondo, Leon D Ortiz, and Kalman Kovacs

Introduction Pituitary adenomas (PAs) arise in different adenohypophyseal cells and represent 15% of intracranial tumors ( Melmed 2011 , Osamura 2017 a ). The majority are slow-growing, noninvasive and benign neoplasms; however, several

Free access

Michael Solarski, Fabio Rotondo, William D Foulkes, John R Priest, Luis V Syro, Henriett Butz, Michael D Cusimano, and Kalman Kovacs

that account for 0.5% of all ovarian neoplasms. They are the most virilizing tumor of the ovary and approximately 50% have been shown to be endocrine-inactive tumors, but no data are available to show what percentage of DICER1 mutation-positive cases

Free access

Halfdan Sorbye, Grace Kong, and Simona Grozinsky-Glasberg

-term toxicity. 177 Lu-DOTA-octreotate (LuTathera) has recently obtained regulatory approval for patients with progressive metastatic grade 1–2 GEP NET. High-grade gastroenteropancreatic neuroendocrine neoplasms: NET G3 and NEC Gastroenteropancreatic

Free access

Pedro Weslley Rosario, Gabriela Franco Mourão, Maurício Buzelin Nunes, Marcelo Saldanha Nunes, and Maria Regina Calsolari

Introduction Recently, it was proposed that some papillary thyroid carcinomas (PTC) will no longer be termed ‘cancer’ and instead be called ‘noninvasive follicular thyroid neoplasm with papillary-like nuclear features’ (NIFTP) ( Nikiforov et

Free access

Ashley K Clift and Andrea Frilling

Introduction Neuroendocrine neoplasms (NEN) represent a heterogeneous class of tumours that arise from nigh ubiquitously dispersed neuroendocrine cells, which may be stratified into clinically meaningful sub-groups on the basis of their